About this trial
This study is a multinational, multicenter, randomized, clinical superiority trial. Patients with a GEJ type II tumor resectable by both transthoracic esophagectomy and transhiatal extended gastrectomy will be enrolled in the trial.Type II tumors are defined as tumors with their midpoint between ≤1 cm proximal and ≤2 cm distal of the top of gastricfolds on preoperative endoscopy. Patients will be included in one of the participating European sites and are randomized to either transthoracic esophagectomy or transhiatal extended gastrectomy.
Patient Profile
Patients with histologically proven adenocarcinoma of the GEJ type II, resectable by both transthoracic esophagectomy andtranshiatal extended gastrectomy according to the local surgical investigator
Where’s this trial being run?
St James’s Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | CARDIA Trial |
|---|---|
| Number: | 24-16 |
| Full Title: | A multinational, prospective, randomized, clinical trial comparing transthoracic esophagectomy with transhiatal extended gastrectomy in adenocarcinoma of the gastroesophageal junction (GEJ) type II |
| Principal Investigator: | Ms Claire Donohoe |
|---|---|
| Type: | Collaborative |
| Sponsor: | University of Cologne |
| Recruitment Started: |
Global: Ireland: To be confirmed |
| Global Recruitment Target: | To be confirmed |
|---|---|
| Ireland Recruitment Target: | To be confirmed |